Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%

Alteplase vs urokinase

Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema

Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).

1 finding from 1 review

Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
OR 0.46 [0.04, 5.24]
1 study · 99 participants
Low

Alteplase vs urokinase

Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema

Alteplase showed no clear difference in overall treatment failure, including mortality, thoracic surgery or… compared with urokinase (low certainty).

1 finding from 1 review

Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
OR 3.02 [0.89, 10.27]
1 study · 99 participants
Low

Alteplase vs urokinase

Serious adverse events · adult parapneumonic effusions and empyema

Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).

1 finding from 1 review

Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
OR 5.61 [1.16, 27.11]
1 study · 99 participants
Low

Alteplase vs urokinase

All‐cause mortality · adult parapneumonic effusions and empyema

Alteplase showed no clear difference in mortality compared with urokinase (low certainty).

1 finding from 1 review

Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
OR 0.94 [0.18, 4.89]
1 study · 99 participants
Low